. 2019 Aug;94(4):361-364.

doi: 10.1016/j.diagmicrobio.2019.02.012. Epub 2019 Feb 19.

No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis

Yu Pang¹, Wei Jing², Jie Lu³, Zhaojing Zong¹, Fengmin Huo¹, Lingling Dong¹, Guangming Dai¹, Yunxu Li¹, Hairong Huang⁴, Naihui Chu⁵

Affiliations

¹ National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
² Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
³ Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
⁴ National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. Electronic address: huanghairong@tb123.org.
⁵ Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. Electronic address: dongchu1994@sina.com.

PMID: 30876684
DOI: 10.1016/j.diagmicrobio.2019.02.012

No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis

Yu Pang et al. Diagn Microbiol Infect Dis. 2019 Aug.

. 2019 Aug;94(4):361-364.

doi: 10.1016/j.diagmicrobio.2019.02.012. Epub 2019 Feb 19.

Authors

Yu Pang¹, Wei Jing², Jie Lu³, Zhaojing Zong¹, Fengmin Huo¹, Lingling Dong¹, Guangming Dai¹, Yunxu Li¹, Hairong Huang⁴, Naihui Chu⁵

Affiliations

¹ National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
² Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
³ Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
⁴ National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. Electronic address: huanghairong@tb123.org.
⁵ Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. Electronic address: dongchu1994@sina.com.

PMID: 30876684
DOI: 10.1016/j.diagmicrobio.2019.02.012

Abstract

Purpose: We explored the potential synergistic effect of bedaquiline (BDQ) combined with moxifloxacin (MFX), gatifloxacin (GAT), clofazimine (CLO), and linezolid (LZD) for treatment of extensively drug-resistant tuberculosis (XDR-TB).

Methods: Of 191 XDR-TB isolates, 20 exhibiting minimal inhibitory concentration (MIC) values ≥0.063 μg/mL for BDQ were selected to study potential synergistic, additive, or antagonistic drug effects using a checkerboard assay.

Results: Antagonism occurred in 14 (70.0%), 0 (0.0%), 13 (65.0%), and 4 (20.0%) XDR-TB isolates for BDQ-MFX, BDQ-GAT, BDQ-LZD, and BDQ-CLO combinations, respectively.

Conclusion: Our in vitro data demonstrate no observed synergistic effects against XDR-TB for drug combinations that included BDQ in combination with MFX, GAT, LZD, or CLO.

Keywords: Bedaquiline; Extensively drug resistant; Synergy; Tuberculosis.

PubMed Disclaimer

Cited by

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
Mudde SE, Ayoun Alsoud R, van der Meijden A, Upton AM, Lotlikar MU, Simonsson USH, Bax HI, de Steenwinkel JEM. Mudde SE, et al. J Infect Dis. 2022 Jun 1;225(11):1876-1885. doi: 10.1093/infdis/jiab101. J Infect Dis. 2022. PMID: 33606880 Free PMC article.
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques.
Abdelaal HFM, Berube BJ, Podell BK, Harband MH, Gary HE, Perez-Jaimes M, Ackart DF, Reese VA, Larsen SE, Pecor T, Wilkins DZ, Parish T, Maloney-Norcross SE, Mecham JB, Hickey AJ, Baldwin SL, Coler RN. Abdelaal HFM, et al. NPJ Antimicrob Resist. 2024 Dec 16;2(1):49. doi: 10.1038/s44259-024-00066-z. NPJ Antimicrob Resist. 2024. PMID: 39843983 Free PMC article.
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Bigelow KM, Tasneen R, Chang YS, Dooley KE, Nuermberger EL. Bigelow KM, et al. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01178-20. doi: 10.1128/AAC.01178-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32690647 Free PMC article.
Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis.
Margaryan H, Evangelopoulos DD, Muraro Wildner L, McHugh TD. Margaryan H, et al. Microorganisms. 2022 Feb 26;10(3):514. doi: 10.3390/microorganisms10030514. Microorganisms. 2022. PMID: 35336089 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis

Affiliations

No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis

Authors

Affiliations

Abstract

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical